Program Description
In this panel discussion, experts will explore recent clinical evidence on novel and emerging pharmacotherapeutic approaches of HER2-directed therapies. The impact of recent evidence and therapeutic advancements, along with identifying key challenges to their implementation in everyday practice, will be discussed, covering concepts such as individualized treatment selection and sequencing in second-line and subsequent settings. The panel will also debate critical questions such as whether all HR+ patients should receive testing for HER2-ultralow, providing approaches to identify these patients, interpret results, select appropriate therapy, ensure appropriate mutational testing, and effectively counsel patients.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: July 31, 2025
Expiration date: July 31, 2026
Time to complete activity: 0.5 hour
Learner level: Intermediate, Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze recent clinical updates on novel and emerging pharmacotherapeutic approaches for HER2-expressing metastatic breast cancer
- Explain the impact of recent evidence and/or therapeutic advancements in HER2-expressing metastatic breast cancer and challenges to implementation
- Identify key considerations for the evaluation and integration of therapeutic changes in HER2-expressing metastatic breast cancer through pharmacist-directed initiatives
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here